ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

RGC Regencell Bioscience Holdings Ltd

8.12
0.03 (0.37%)
05 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Regencell Bioscience Holdings Ltd NASDAQ:RGC NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.03 0.37% 8.12 7.67 8.15 8.56 6.9301 7.74 67,446 00:47:46

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

28/02/2023 2:16pm

Edgar (US Regulatory)


 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of February 2023

 

Commission File Number: 001-40617

 

Regencell Bioscience Holdings Limited

 

11/F First Commercial Building

33-35 Leighton Road

Causeway Bay, Hong Kong

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F      Form 40-F

 

 

 

 

 

 

Appointment of Chief Business Officer

 

Regencell Bioscience Holdings Limited, a company incorporated under the laws of the Cayman Islands (the “Company” or “Regencell”), promoted Yat-Pui Au (“Mr. Au”) from senior vice president of the Company to chief business officer of the Company, effective February 1, 2023.

 

“We are delighted to promote Yat-Pui to the role of chief business officer. Yat-Pui is an accomplished professional in strategic management and business operations, with a track record in the physical security and property management sectors industry. We believe Yat-Pui will continue to contribute to our growth,” said Yat-Gai Au, the chief executive officer and chairman of the board of directors of the Company.

 

Mr. Au has more than 24 year experience in strategic management and business operations. He joined Regencell in October 2021. Prior to Regencell, he worked at various leading roles in the physical security and property management sectors, where he implemented digital and cloud-based CRM solutions, completed major technology projects for governmental/institutional/private sectors, and streamlined business operations across marketing, finance, IT, human resources and operations departments. Mr. Au started his career as a consultant analyst for Computer Sciences Corporation for IT/MIS integrations and deployment. Mr. Au obtained his bachelor’s degree in legal studies from University of California, Berkeley. Mr. Au is the brother of Yat-Gai Au, the chief executive officer and chairman of the board of directors of the Company.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: February 28, 2023

 

  Regencell Bioscience Holdings Limited
     
  By:

/s/ Yat-Gai Au

  Name:  Yat-Gai Au
  Title: Chief Executive Officer and Chairman of the Board of Directors

 

 

 

2

 

1 Year Regencell Bioscience Chart

1 Year Regencell Bioscience Chart

1 Month Regencell Bioscience Chart

1 Month Regencell Bioscience Chart

Your Recent History

Delayed Upgrade Clock